il 13 (R&D Systems)
Structured Review

Il 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1587 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+13/Mouse+IL-6+Quantikine+ELISA+Kit/pmc13122667-77-39-40
Average 97 stars, based on 1587 article reviews
Images
1) Product Images from "Nrf2 pathway mediates copper oxide nanoparticle-induced exacerbation of allergic asthma"
Article Title: Nrf2 pathway mediates copper oxide nanoparticle-induced exacerbation of allergic asthma
Journal: Redox Biology
doi: 10.1016/j.redox.2026.104180
Figure Legend Snippet: Effects of CuONPs on allergic inflammation and oxidative stress in OVA-induced asthmatic mice. (A) Airway hyperresponsiveness assessed as total respiratory system resistance in response to methacholine challenge (10, 20, and 40 mg/mL). (B–F) Total and differential inflammatory cell counts in BALF. (G–L) IL-1β, IL-6, TNF-α, IL-4, IL-5, and IL-13 levels in BALF, measured by ELISA. (M and N) Total IgE and OVA specific IgE levels in serum. (O and P) MDA levels and SOD activity in lung tissue. Data are presented as means ± SD (n = 6 mice/group). ∗∗ p < 0.01 and ∗∗∗ p < 0.001 versus NC group. # p < 0.05, ## p < 0.01, and ### p < 0.001 versus OVA group.
Techniques Used: Enzyme-linked Immunosorbent Assay, Activity Assay
Figure Legend Snippet: Effects of Nrf2 overexpression on allergic inflammation and oxidative stress in CuONP-exposed asthmatic mice. (A) Immunofluorescence analysis of lung tissue from mice administered PBS or AAV2/8-GFP via intratracheal instillation. (B) Airway hyperresponsiveness assessed as total respiratory system resistance in response to methacholine challenge (10, 20, and 40 mg/mL). (C–G) Total and differential inflammatory cell counts in BALF. (H–M) IL-1β, IL-6, TNF-α, IL-4, IL-5, and IL-13 levels in BALF, measured by ELISA. (N and O) Total IgE and OVA specific IgE levels in serum. (P and Q) MDA levels and SOD activity in lung tissue. Data are presented as means ± SD (n = 3 mice/group for panels A; n = 6 mice/group for panels B–Q). In panel B, ## p < 0.01 indicates significant differences between GFP-NC and GFP-OVA, and ∗∗ p < 0.01 indicates significant differences between GFP-OVA + CuONPs and Nrf2-OVA + CuONPs. For panels C–Q, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001 indicate significant differences between AAV-GFP and AAV-Nrf2 within each condition.
Techniques Used: Over Expression, Immunofluorescence, Enzyme-linked Immunosorbent Assay, Activity Assay
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Nrf2 pathway mediates copper oxide nanoparticle-induced exacerbation of allergic asthma Article Snippet: .. BALF was centrifuged at 300× g for 10 min at 4 °C, and the supernatant was stored for cytokine analysis using commercially available enzyme-linked immunosorbent assay (ELISA) kits to quantify IL-1β, IL-6, tumor necrosis factor (TNF)-α, IL-4, IL-5, and Article Title: Nrf2 pathway mediates copper oxide nanoparticle-induced exacerbation of allergic asthma. Article Snippet: .. BALF was centrifuged at 300×g for 10 min at 4 ◦C, and the supernatant was stored for cytokine analysis using commercially available enzyme-linked immunosorbent assay (ELISA) kits to quantify IL-1β, IL-6, tumor necrosis factor (TNF)-α, IL-4, IL-5, and Recombinant:Article Title: Serglycin modulates inflammation and metabolism in macrophages Article Snippet: Cells were then polarized to either an M0 (resting) or M1 (proinflammatory) state by culturing in RPMI medium containing either vehicle (M0) or 20 ng/mL IFN-γ (PeproTech, Cat. No. 300-02) and 100 ng/mL LPS (Sigma-Aldrich, Cat. No. L2630). .. M2 polarization was induced using 20 ng/mL IL-4 (Recombinant Human IL-4 Protein, Sigma-Aldrich/Merck, Cat. No. SRP3093) and 20 ng/mL Activation Assay:Article Title: Discovery of metabolites produced by reactions between central carbon metabolites and cysteine that mark inflammatory macrophages Article Snippet: For classical activation, BMDMs were treated with 50 ng/mL LPS (E. coli O111:B4; Sigma-Aldrich, L3024) and 30 ng/mL recombinant mouse IFNγ (R&D Systems, 485-MI-100) for the indicated durations. .. For alternative activation, BMDMs were treated with with 20 ng ml −1 IL-4 (cat. no. 404-ML, R&D Systems) and 20 ng ml −1 |